51 – 60 of 285
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Register data support the long-term safety of the use of ultra-hypofractionated radiotherapy for localised prostate cancer previously seen in the phase 3 trial HYPO-RT-PC : ESTRO 2024 congress report
(2024)
- Other contribution › Web publication
-
Mark
Cost of Illness of Head and Neck Cancer in Sweden
- Contribution to journal › Article
-
Mark
Morbiditet från urinvägar och tarm enligt registerdata efter ultrahypofraktionerad strålbehandling för lokaliserad prostatacancer vid 10 år i HYPO-RT-PC-studien
(2024) Onkologidagarna 2024
- Contribution to conference › Poster
-
Mark
Hematological and renal toxicity in mice after three cycles of high activity [177Lu]Lu-PSMA-617 with or without human α1-microglobulin
- Contribution to journal › Article
-
Mark
Feasibility and constraints of Bragg peak FLASH proton therapy treatment planning
- Contribution to journal › Article
-
Mark
Pre- and Postoperative Antioxidant Use, Aryl Hydrocarbon Receptor (AhR) Activation and Clinical Outcome in Different Treatment Groups of Breast Cancer Patients
- Contribution to journal › Article
-
Mark
Feasibility of 177Lu activity quantification using a small portable CZT-based gamma-camera
- Contribution to journal › Article
-
Mark
Beyond Average : a-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer
- Contribution to journal › Article
-
Mark
Minimal invasive LASER-resection vs. radiotherapy as primary treatment of early glottic cancer. A population-based study with, up to 16 years follow up of survival, rate of laryngectomy and voice function
- Contribution to journal › Article
-
Mark
In vivo MRI and PET imaging in a translational ILD mouse model expressing non-resolving fibrosis and bronchiectasis-like pathology after repeated systemic exposure to bleomycin
- Contribution to journal › Article
